PELNSEPiramal Enterprises Limited· PharmaceuticalsHighNeutral
Announced Tue, 6 May · 17:18 IST

Piramal Enterprises Limited has informed the Exchange regarding Outcome of Board Meeting for approval of Financial Results.

Emphasis Of MatterRevenue DeclineExceptional ItemPat NegativeResults View source PDF
Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

The Board approved audited standalone and consolidated financial results for the year ended 31st March 2025. Standalone total income for FY25 was Rs. 2,257.94 crores (down from Rs. 3,825.21 crores in FY24, largely because FY24 had one-time gains from the sale of Shriram stakes worth Rs. 1,725 crores). Standalone profit after tax rose to Rs. 503.73 crores from Rs. 474.05 crores in FY24, but Q4 FY25 standalone PAT was a loss of Rs. 23.33 crores. The Board recommended a final dividend of Rs. 11 per share (550%) on a Rs. 2 face value, subject to shareholder approval. Joint statutory auditors (Suresh Surana & Associates LLP and Bagaria & Co LLP) issued an unmodified opinion on both sets of results, with two emphasis-of-matter notes: (1) subsidiary Piramal Finance Limited's conversion from HFC to NBFC-ICC (RBI approval received 4 April 2025), and (2) deferred tax assets recognised on unadjusted tax losses depending on future profitability. Gross NPA stood at 3.18% and net NPA at 0.93%.

Likely market impact

A clean audit opinion and a higher full-year PAT support confidence, but the sharp drop in total income and a Q4 loss (driven by absence of last year's exceptional gains and higher finance costs) may draw investor attention. The 550% final dividend and the HFC-to-NBFC conversion of PFL are positive developments for shareholders, while the emphasis on deferred tax recoverability is a watchpoint.